Pieris receives $5M milestone from Seagen for Phase 1 start of CD228 x 4-1BB bispecific SGN-BB228

PALVELLA THERAPEUTICS, INC.

Achieved $5M milestone from Seagen upon first patient dosed in Phase 1 study of SGN-BB228 (PRS-346).
Phase 1 trial (NCT05571839) evaluates SGN-BB228 in advanced melanoma and other solid tumors.
This is the first clinical start in Pieris' collaboration with Seagen; two additional programs ongoing.
Pieris has an opt-in option for U.S. co-promotion on one program in the collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.